Abstract Objective: Our objectives were to determine factors which influence survival after resectional surgery in patients with cancer of the oesophagus and cardia. Patients and method: 562 consecutive patients with primary cancer of the oesophagus or gastric cardia (oesophago-gastric junction) undergoing resectional surgery and reconstruction of the oesophagus were studied. Operative approach depended on tumour location, the aim being complete resection of the tumour and associated lymph nodes. Postoperative staging was based on tumour, nodes and metastasis (TNM) classification. Results: There were 342 males and 220 females, aged 61.8 ___ 12_8 years. Histology of the tumours was: squamous cell carcinoma 49%, adenocarcinoma 47.5% and other tumours 3.5%. The location of tumours within the oesophagus was" cervical (n = 32), upper thoracic (n = 18), middle thoracic (n = 241) and lower thoracic and gastric cardia (n = 271). Of the tumours 16% were stage I, 10% stage II and 74% stage III. Hospital mortality rate was 9% overall, significantly higher in cervical tumours (cervical tumours versus lower and or middle oesophageal tumours: P < 0.05), the elderly (age >75 years versus age <75 years: P<0.05) and stage III disease (stage III versus stage I: P<0.001). The overall 5-year survival rate was 18%. There was no correlation between tumour histology, location or type of operation and long-term survival. Survival disease-free for 5 years or more was 73% for stage I, 15.8% for stage II and 6% for stage III. The only significant correlation was between the stage of disease and long-term survival (stage I versus stage III P<0.001, stage I versus stage I I P < 0_05).
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Introduction
Carcinoma of the oesophagus is associated with one of the worst prognoses amongst all common gastro-intestinal malignancies. Advances in anaesthesia, intensive care and the surgical techniques of oesophagectomy have contributed significantly to lowering the immediate morbidity and mortality from oesophageal surgery but have not improved the overall long-term survival [13] . Advances in the management of malignant disease with multi-modality treatments have yet to make a significant impact on long-term survival, which remains at about 10% [8, 17] .
We present the results of a review of 20 years' experience in operating on malignancies of the oesophagus and gastric cardia. In this review we have focused specifically on the factors which influence long-term suvival.
Patients and methods
All patients undergoing oesophageal resection for primary oesophageal malignancy, including those of the gastro-esophageal junction (here referred to as cardia) during the study period September 1970-September 1990 are included. A full clinical history, examination, biochemical and haematological profile, radiological imaging of the tumour and metastasis screen were performed in all cases. Every patient underwent assessment oesophagoscopy, and bronchoscopy was performed in those with cervical, upper or middle thoracic oesophageal tumour. Further investigation was performed when indicated. During the time course of the study additional modalities of imaging for staging became available, such as computerised axial tomography and magnetic resonance imaging. The more advanced imaging techniques identified a higher proportion of the patients with metastatic spread preoperatively and allowed for the planning of nonresectional therapies. Patients identified at the time of surgery as having metastatic spread received a palliative non-resectional procedure_ Our policy has been to offer resectional surgery to those patients without evidence of metastatic spread of disease or gross local involvement provided they were fit enough, advanced age alone was not considered to be a contraindication. Superior imaging techniques have made no alteration upon the overall surgical policy. All assessment and treatment was carried out by a single team,
Operative technique
Surgery in all patients was undertaken with curative intent, with complete excision of the tumour and free margin of at least 5 cm en bloc with associated regional lymph nodes (which, in practice, always involved the mediastinal and coeliac axis). In post-cricoid carcinomas the operation was performed as a combined approach, the head and neck surgical team carrying out laryngectomy and establishment of a permanent tracheostomy simultaneously with the thoracic team performing the laparotomy, preparing the gastric (or colonic) tube, oesophagectomy without thoracotomy, delivery of the tube into the neck and, finally, carrying out the anastomosis between the tube and the pharyngeal remnant [14] . Tumours of the cervical oesophagus and upper thoracic oesophagus were resected using a three-stage (McKeown) technique [9] . Mid-thoracic tumours were approached using a two-stage (Lewis) operation [6] . Lower thoracic tumours extending to the cardia were operated upon either using a two-stage technique, or via a left thoracophrenotomy approach [16] . In some cases of tumours of the cardia, when there was evidence of subdiaphragmatic extension along the lesser curvature, subtotal oesophagectomy was combined with a total gastrectomy [11] . Reconstruction in cervical oesophageal neoplasia was usually with stomach, but colon was occasionally employed. In all other cases gastric remnant tubes were used for reconstruction, except in those with a total gastrectomy when a Roux-en-Y loop was fashioned. In all cases stapling devices were used for the mobilisation and preparation of gastric tubes but oesophageal anatomoses were carried out using a two-layer handsewn interrupted suture technique. All resected specimens were submitted for histopathological staging using the American Joint Committee's tumour nodes metastasis (TNM) system 1988 and 1983 schedules shown in Table 1 [1] . It should be noted that during this study the classification of stage IIa disease had not been determined. No patients received adjuvent therapy.
Post operative follow up Every patient was followed up after discharge from hospital at intervals of 1 month, 3 months, and thereafter every 6 months for 5 years or until death. Those who survived for more than 5 years were seen annually_ Patients with symptoms suggestive of recurrent turnout were investigated and managed appropriately. Stage IV Any T Any N M1
Statistics
Data were assessed using chi-square tests, Fischer's exact test and Mann-Whitney analysis. All results are shown as a mean_+one standard deviation_ A probability value of less than 0_05 is considered to be significant, a value of less than 0.001 is considered to be highly significant.
Results
There were no significant differences in the pattern of referral during the study period. The study group consisted of 562 consecutive patients selected for surgery from a group of 1099 consecutive referrals with primary malignancy of the oesolShagus or gastric cardia. There were 342 male and 220 female patients, the mean age was 61.8 _+12.8 years.
The tumours were divided approximately equally between squamous (n = 276) and adenocarcinoma (n = 268). In addition to these groups there was a small number of "unusual tumours": mixed tumours and undifferentiated tumours (n = 12), lymphoma (n = 3), small cell carcinoma (n = 3). In the cervical and upper oesophagus squamous cell tumours predominated and in the lower third there were significantly more adenocarcinomas (cervical or upper third thoracic oesophagus versus lower third thoracic oesophagus P < 0.05 for both).
The overall distribution of tumour staging was stage I 15.8% (n---89), stage II 10% (n=57) and stage III 74% (n = 416). There was a significantly higher proportion of stage III tumours in the cervical oesophageal group as compared to the lower and middle thoracic oesophageal groups. The distribution of the small cervical group is strongly skewed by a number of postcricoid carcinomas, which are all stage III (cervical stage III versus middle thoracic oesophagus stage III P<0.05; cervical stage III versus lower thoracic oesophagus stage III P < 0.05). There were no significant differences in staging of either of the two principal turnout types (adenocarcinoma type ! versus squamous cell carcinoma stage I P > 0.05, adenocarcinoma stage II versus squamous cell carcinoma stage II P > 0.05, adenocarcinoma stage III versus squamous cell carcinoma stage III P > 0.05). The overall hospital or 30-day mortality rate was 9%. There was a significantly higher mortality (16%) in the 112 elderly patients (age >75 years versus age <75 years: P < 0.05). The in-hospital mortality for cervical carcinoma was 15%, postcricoid carcinomas 14.3%, upper thoracic 10%, mid and lower thoracic, 7 % and 5 % respectively. Significantly higher mortality was associated with tumours of the cervical and upper thoracic oesophagus compared to the lower thoracic oesophagus (cervical oesophageal surgery versus lower thoracic oesophageal surgery P < 0.05, upper thoracic oesophageal surgery versus lower thoracic oesophageal surgery P<0.05), Stage I disease was associated with a significantly lower in-hospital mortality (2.94%) as compared with stage II (9.1%) and stage III (9.89 %) tumours (stage III versus stage I: P < 0.001; stage II versus stage I: P<0.05). The most frequent causes of postoperative/in-hospital deaths were respiratory infections. A small number of patients (11%) died from cardiovascular events (myocardial infarction, arrhythmia, stroke and pulmonary embolus). There were two anastomotic leaks, one of whom died in hospital, the other survived.
The 3-and 5-year survival rates are 20.2 and 18% respectively, statistical calculations are based on actual survival for 5 years, details of 3-and 5-year survival are demonstrated in all figures. Histology of the tumour had no effect on the long-term survival (adenocarcinoma versus squamous cell tumours or others P > 0.05, squamous cell carcinoma versus others P>0.05). The type of operation performed had no effect on long-term survival rates (cornparison of any two groups or combination of groups gives P>0.05). The location of tumour had no effect on longterm survival rates (comparison of any two groups or combination of groups gives P>0.05). Disease-free survival for 5 years or more correlated strongly with the stage of disease (stage I versus stage III P<0.001, stage I versus stage II P<0.05, stage 1I versus stage III P>0.05). The actual numbers of patients surviving are detailed in Table 1 -5. The relative profile of the death rate by stage is shown in Fig. 1 .
Discussion
The most fundamental of the controversies surrounding the treatment of oesophageal carcinoma concerns the role of surgery, the selection of patients for surgery and the aim of the operative procedure employed, since the overall prognosis for patients after successful surgical resection remains poor [13] . There is no disagreement that for early stage cancers resectional surgery with its low hospital mortality and good long-term results is the treatment of choice. This is amply documented by the Chinese and Japanese surgeons who, in large series of patients, have demonstrated a good long-term survival [2, 7, 10, 18] . In a previous publication by this team, we have shown that similar results with early oesophageal cancer can be replicated in a European population [12] . Clearly the indication of surgery for stage I disease cannot be questioned. The dis- appointing fact is, however, that in western European countries at presentation and diagnosis only a small proportion of the cases fall into the category of stage I disease [3, 4] . Although patients with stage I disease have a reasonable prognosis, 70% surviving 5 years or more, the much larger proportion of patients with stage III disease brings the 5-year survival rate down to 18% overall in this series. Obviously, therefore, the long-term survival of any group of mixed oesophageal cancers will be determined by the percentage of resectability, then principally by the proportion of patients with stage I disease within the resected group. It should be noted that in this series we report nearly 16% of the resected cases had stage I disease. This comprises only 7% of the total referrals during the study period.
The question arises as to whether surgical resection is the most suitable modality of treatment for advanced tumours. For instance, is it justifiable to submit patients with stage III disease to the pain and expense of oesophagectomy when this series demonstrates that 40% will have died within the 1 st year and there is onty a 6% chance of longterm survival? To correctly answer this question one should first elaborate that, at the present time, it seems that a patient's only chance of achieving long-term survival, if merely 6%, lies with surgical resection. Secondly, in the majority, if not operative surgery what comparable palliation can we offer such patients? There is no firm evidence as yet that radiotherapy and/or chemotherapy without surgery can offer a better solution to the problem. When multimodality therapy is employed as an adjunct to surgery there is some suggestion that in small subsets of patients this may improve survival [8, 17] . The major problem with combination therapy is the accuracy of initial assessment of stage of disease and evaluation of the effect of adjuvent treatment on alteration of the stage of disease (so called down-staging). The ideal would be to identify accurately patients with stage III disease preoperatively and to undertake a carefully controlled randomised trial to test the true efficacy of adjuvant therapy.
In our study we analysed the influence of a variety of factors such as location of the tumour, histology, type of operation performed and pathological staging of the disease. Whilst these factors individually or in concert have affected the immediate mortality, none except the pathological stage of the tumour significantly affected long-term survival. If therefore we are to improve the overall longterm results, serious efforts have to be made in either one or all of the following:
1_ Increasing the awareness of the population and those involved with primary health care that dysphagia is the earliest presenting symptom in the majority of cases including early stage tumour, as has been shown by a number of authors [10, 12] . This symptom should be fully investigated. 2. The introduction of an adjuvent therapy to surgery in a selected subset with stage III disease with the aim of "down-staging" the disease and thus up-grading the longterm survival rate. 3. Establishment of a cost effective programme of screening in an effort to identify early cases and those considered to be most at risk.
We believe that a randomised trial to compare the efficacy of various palliative treatments should be a priority since, for the foreseeable future, the overall majority of patients with oesophageal cancer will require palliative treatment. We conclude that unless the stage of disease can be more accurately assessed preoperatively patients should be given the option of surgery unless, for reasons of general health or because of extent of tumour or metastases, surgery is not feasible_ Discussion Dr. H. Ellis (Boston, USA): It gives me great pleasure to discuss the paper presented so nicely by Mr. Sharpe from Professor Moghissi's Department, for I agree with most of their conclusions regarding treatment of this complicated and discouraging disease. I too have favored an aggressive surgical approach to the disease and have also found that the only significant prognostic feature, in terms of long-term survival, is the stage of the disease at the time of operation.
Let me briefly review my own personal experience and compare it to that which has just been presented. Our operability rate is somewhat higher, being in the neighborhood of 80-85%. From January 1970 to July 1994, 422 patients with carcinoma of the esophagus and cardia were operated on, 379 (91.1%) of whom underwent resection. The 30-day mortality was 2.6% with another 1.6% failing to leave the hospital for an overall mortality of 4%, slightly lower than just reported by you. However, our 5-year survival rate is no different than what the authors have reported, it being 20.8% with 23.3% of those undergoing a "curative" resection surviving 5-years. Survival is closely related to the stage of the disease, it being 50.8% for stage I patients but only 13_6% for those in stage III. No stage IV patients survived 5 years. Other variables, including site of the tumor, duration of symptoms, and cell type had no statistically significant influence on long-term survival, leading me to the conclusion that early diagnosis rather than expanding the extent of the operative procedure by a radical "en bloc" technique or the use of neoadjuvant therapy will have a significant impact on long-term survival following resection.
This has been born out in our experience with patients developing carcinoma in Barrett's esophagus while under endoscopic surveillance. We have recently published a comparison of such patients undergoing resection who had been under endoscopic surveillance compared with those who had not, the 5-year survival rate of the former being 62.2% as opposed to 20%.
I have two questions. What has been your experience with carcinoma in Barrett's esophagus? This now accounts for 1/3 of all intrathoracic esophageal malignancies coming to operation on my service. In view of the fact that early diagnosis seems to be so important prognostically, what role do you think radical "en bloc" resection or neoadjuvant therapy should play in the treatment of this disease? Do you agree with me that early diagnosis is, in all likelihood, the clue to long-term survival following resection?
Mr. Sharpe: I will take your questions in reverse order. Yes, the key to this problem is picking out the stage I tumors. It all revolves around finding out who has got stage I disease, because we can do well with those patients. The trouble, as I see it, with current imaging and current technology, is we don't know which ones are stage III and which ones are stage I when we go in for surgery on them. We end up offering surgery to everybody. It is probable that there is a subgroup in the stage III who would be better palliated by other forms of therapy. Whether that is going to be endoluminal radiotherapy and laser or some combination of photodynamic therapy and laser, I don't know, but the key, I agree, is the identification of early disease.
With regard to Barrett's esophagus, that's a little bit more of a problem. That depends on your definition of Barrett's esophagus, and I know Mr. Moghissi, whose data on this is thorough, has written extensively on the subject. We did not select out the Barrett's for statistical analysis in this group, therefore I cannot answer your question properly. My impression is that the people with Barrett's esophagus do better because we are attacking them earlier because they are being picked up sooner.
Dr. Ellis: The two last questions I don't think you answered. What about neo-adjuvant therapy, its role in trying to improve long-term survival? And how do you feel about the radical en bloc approach that has been espoused by a few of my colleagues in the United States?
Mr. Sharpe: Neo-adjuvant therapy, again, turns around the staging problem. We talk about down-staging tumors. You don't know what the stage is to start with, so how would you know what you have down-staged it to? It is impossible to tell_ Until we can stage them better we won't know whether neo-adjuvant therapy is effective, but even then, an en bloc resection: it is bolting the stable door after the horse has bolted. We need to pick them up early, not attack them more aggressively. The operations work if we get early carcinomas.
Mr. Moghissi: I was going to comment on the question Professor Ellis asked about Barrett's. I have always been a bit of a loner on the question of definition of Barrett's, because I started with the anatomical description, which Barrett intended, rather than the endoscopic, which people came to believe in in the later years. Having said that, all the Barrett's adenocarcinoma, even according to my own description, have been the people who have been retrospectively found to be Barrett's esophagus adenocarcinoma and not prospectively picked up. In the U.K. we have not, so far, followed the people with B arrett's %soph-agus". I find another difficulty that appeared is columnar epithelium with one or two atypical cells in the young person. Now, am I going to do an esophagectomy on that person? I think a lot of people believe I should, but I am not certain in my own mind. So that is the business of my Barrett's experience.
Mr. J. Thorpe (Sheffield, England): I would like to comment on that last issue, Keyvan. I have only resected three cases of three severe dysplasia in Barrett's oesophagus_ They have all subsequently had adenocarcioma under the mucosa. So you are dependent on the endoscopic appearances and how aggressive the endoscopist is. I am concerned about severe dysplasia as there may well be frank adenocarcinoma in the submucosa.
